Neurona Therapeutics | NRTX-1001 Inhibitory Neuron Cell Therapy
Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated …
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001
Apr 3, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy product candidates with the potential to provide long-term targeted repair of the nervous …
Neurona Doses First Patient in CIRM-Funded Bilateral Epilepsy ...
Jun 20, 2025 · The new bilateral trial builds on encouraging results from Neurona’s ongoing trial—which observes seizures that originate from one side of the brain—and is also funded …
Cell therapy biotech bags $102M to fund phase 3 epilepsy plans
Apr 3, 2025 · Neurona has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 ...
Apr 3, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy product candidates with the potential to provide long-term targeted repair of the nervous …
Neurona Therapeutics - LinkedIn
About us Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders.
Neurona Therapeutics Presents Positive Clinical Data Update ...
Apr 8, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapies with the potential to provide long-term targeted repair of the nervous system following a single …